More good news from RNAi company Isis

Isis has been on a good-news roll lately, and today is no exception. The company announced positive results from a Phase II open-label extension trial of of ISIS 301012, a cholesterol-lowering drug for with familial hypercholesterolemia. The study included 16 patients who had participated in an earlier Phase II study of the drug. These patients received weekly doses of ISIS 301012 for as long as six months and didn't experience any new or worsening adverse events.

"We are particularly pleased to have had such an uneventful experience with patients in the long-term study. Until now, the longest exposures to ISIS 301012 had been three months, and now to have patients dosed for a total of more than six months without any tolerability issues is quite reassuring," stated John J.P. Kastelein, M.D., Ph.D., a principal investigator for the studies. "Of course, we will all be eager to see more patients and longer exposure times to strengthen our confidence that ISIS 301012 could truly be a transformational new drug for the treatment of refractory high cholesterol."

- see the release from Isis for more

Related Articles:
Isis touts positive cholesterol data in LDL study. Report
RNAi leaders Isis, Alnylam form new company. Report
Isis acquires Symphony GenIsis. Report
Isis gains from big RNAi deal. Report
Mid-stage cholesterol data sends Isis stock soaring. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.